Coverage dated October 19, 2021 to October 26, 2021
Pfizer vaccines for younger kids expected in Washington next week
Headline from The Columbian, on the newest of 3 developments
OLYMPIA — Health officials in Washington said Wednesday they are expecting about 316,000 doses of kid-sized Pfizer COVID-19 vaccines to arrive in the state next week ahead of the expected final approv
The Columbian's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
3 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
FDA scientists say benefits of Pfizer Covid-19 vaccine 'clearly outweigh' the risks for children ages 5 to 11 - STAT
Headline from STAT ·
Children could soon be eligible for Pfizer COVID-19 vaccine
Headline from Fox5 Atlanta ·
Newest
Pfizer vaccines for younger kids expected in Washington next week
Between June 1 and Sept. 30 of this year, the CDC performed a case-controlled study of Pfizer’s vaccine in adolescents at 19 pediatric hospitals in 16 states, according to the study published on Tuesday.
US says benefit outweighs any risk, no unexpected side effects; panel to vote Tuesday before decision made on authorization; Israel said planning to inoculate kids from December
Federal health regulators said late Friday that kid-size doses of Pfizer’s COVID-19 vaccine appear highly effective at preventing symptomatic infections in elementary school children and caused no unexpected safety issues, as the U.S. weighs beginning vaccinations in youngsters.
Earlier this month, Pfizer/BioNTech asked federal regulators to authorize emergency use of their COVID-19 vaccine for children 5 to 11 years old. Now, that approval could come as soon as tomorrow.
The Food and Drug Administration's (FDA) Vaccine Advisory board will have a meeting on Tuesday discussing the expansion of the Pfizer vaccine for younger kids.
FDA vaccine advisers will meet Tuesday to review data on Pfizer's COVID-19 vaccine for children ages 5-11. A Pfizer study found the vaccine is 91% effective at preventing symptomatic infections.
The FDA advisory board is expected to talk about Pfizer's COVID vaccine for kids on Tuesday. If authorized, kids ages 5-11 would soon be eligible for the shots.
A Food and Drug Administration advisory panel will decide if they'll recommend a dose of the shot to an age group under 12, then the decision moves on to the CDC.
An FDA panel of outside vaccine experts is meeting to determine whether they will recommend COVID-19 shots for the nation’s 28 million children aged 5 to 11.
A study of elementary schoolchildren found the Pfizer shots are nearly 91% effective at preventing symptomatic infection -- even though the youngsters received just a third of the dose given to teens and adults.
WASHINGTON (AP) — Kid-size doses of Pfizer’s COVID-19 vaccine may be getting closer as government advisers on Tuesday began deliberating whether there’s enough evidence that the shots are safe and
A panel of U.S. health advisers on Tuesday endorsed kid-size doses of Pfizer's COVID-19 vaccine, moving the U.S. closer to beginning vaccinations in children ages 5 to 11.
By Jen Christensen, CNN The US Food and Drug Administration’s independent vaccine advisory committee meets Tuesday to discuss if the Pfizer/BioNTech Covid-19 vaccine should be authorized for children ages 5 to 11.
A panel of U.S. health advisers on Tuesday endorsed kid-size doses of Pfizer’s COVID-19 vaccine, moving the U.S. closer to beginning vaccinations in children ages 5 to 11.
The panel's vote is an important regulatory step in getting the vaccine into the arms of millions of children in the United States where schools are largely open for in-person learning. The FDA need not follow the advice of its outside experts, but usually does.
WASHINGTON, DC -- The U.S. Food and Drug Administration's independent vaccine advisory committee is meeting Tuesday to discuss if the Pfizer/BioNTech Covid-19 vaccine should be authorized for children ages 5 to 11.
